Katherine Bowen is an accomplished professional in regulatory affairs, currently serving as Senior Director of Regulatory Affairs at Boyds since September 2022. Prior experience includes pivotal roles at DLRC Regulatory Consultancy, where Katherine held multiple leadership positions such as Head of Regulatory Teams and Principal Consultant from January 2019 to September 2022. Katherine’s expertise encompasses EU regulatory strategy and submissions, particularly for diabetes molecules, developed through previous roles at Eli Lilly and Company from August 2010 to December 2018, as well as positions at Amgen and Deallus. Educational qualifications include a PhD in Neurobiology from the University of Cambridge and a BSc Hons (1st class) in Neuroscience from the University of Nottingham.